1.29
0.03 (2.38%)
0.03 (2.38%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 63,772 |
|
|||||
News | - | ||||||
Day High | 1.29 | Low High |
|||||
Day Low | 1.25 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Moleculin Biotech Inc | MBRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.29 | 1.25 | 1.29 | 1.29 | 1.26 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
133 | 63,772 | $ 1.26 | $ 80,591 | - | 0.817 - 2.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:35:58 | 1 | $ 1.31 | USD |
Moleculin Biotech Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 36.93M | 28.63M | 28.01M | $ - | $ - | -0.59 | -1.50 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 67.50k | 3.10% |
Moleculin Biotech News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MBRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.27 | 1.32 | 1.22 | 1.27 | 41,252 | 0.02 | 1.57% |
1 Month | 1.12 | 1.35 | 1.02 | 1.18 | 66,401 | 0.17 | 15.18% |
3 Months | 1.02 | 1.51 | 0.817 | 1.25 | 107,731 | 0.27 | 26.47% |
6 Months | 1.66 | 1.85 | 0.817 | 1.30 | 101,460 | -0.37 | -22.29% |
1 Year | 1.54 | 2.05 | 0.817 | 1.41 | 93,021 | -0.25 | -16.23% |
3 Years | 0.91 | 8.78 | 0.323 | 1.88 | 1,441,361 | 0.38 | 41.76% |
5 Years | 1.97 | 8.78 | 0.323 | 1.88 | 1,172,632 | -0.68 | -34.52% |
Moleculin Biotech Description
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. |